Phathom Pharmaceuticals (PHAT) Price & Analysis

Compare

543 Followers

PHAT Stock Chart & Stats

$14.57

-$0.22(-3.06%)

At close: Jan 08 4:00 PM EST

$14.57

-$0.22(-3.06%)

Day’s Range― - ―

52-Week Range$2.21 - $16.45

Previous CloseN/A

Volume285.74K

Average Volume (3M)892.92K

Market Cap

$1.01B

Enterprise Value$1.31B

Total Cash (Recent Filing)$135.16M

Total Debt (Recent Filing)$2.71M

Price to Earnings (P/E)―

Beta2.03

Next Earnings

Mar 03, 2026

EPS Estimate

-0.42

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.41

Shares Outstanding71,138,440

10 Day Avg. Volume714,453

30 Day Avg. Volume892,924

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)-2.02

Price to Sales (P/S)9.28

P/FCF Ratio-1.92

Enterprise Value/Market Cap1.30

Enterprise Value/Revenue8.91

Enterprise Value/Gross Profit10.22

Enterprise Value/Ebitda-6.44

Forecast

1Y Price Target

$25.40

Price Target Upside74.33% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-3.11

Revenue Forecast (FY)$170.39M

Bulls Say, Bears Say

Bulls Say

Operational EfficiencyThe company effectively reduced operating expenses by 43% quarter over quarter, indicating successful commercial restructuring.

Prescription GrowthConsistent growth in filled VOQUEZNA prescriptions, with a 28% increase over the previous quarter, highlights effective commercial execution.

Revenue GrowthPHAT reported $49.5M in 3Q25 V oquezna revenue, above the FactSet consensus of $47.0M.

Bears Say

Prescription Fulfillment ChallengesConcerns exist over prescriptions being written but not filled due to potential insurance coverage issues and patient follow-up challenges.

Phathom Pharmaceuticals News

Phathom Pharmaceuticals initiated with a Strong Buy at Raymond James

Raymond James analyst Martin Auster initiated coverage of Phathom Pharmaceuticals (PHAT) with a Strong Buy rating and $28...

2d ago

PHAT

Phathom Pharmaceuticals initiated with an Equal Weight at Barclays

Barclays analyst Jenna Davidner initiated coverage of Phathom Pharmaceuticals (PHAT) with an Equal Weight rating and $16 price...

5d ago

PHAT

Phathom announces first patient dosed in Phase 2 pHalcon-EoE-201 trial

Phathom Pharmaceuticals (PHAT) announced the first patient has been dosed in its Phase 2 pHalcon-EoE-201 clinical trial evaluating...

1M ago

PHAT

Phathom Pharmaceuticals Begins Phase 2 EoE Trial

Phathom Pharmaceuticals ( ($PHAT) ) has provided an announcement. On November 4, 2025, Phathom Pharmaceuticals announced the commencement...

1M ago

PHAT

Phathom Pharmaceuticals’ Q3 Earnings: Strong Growth Amid Challenges

Phathom Pharmaceuticals, Inc. (($PHAT)) has held its Q3 earnings call. Read on for the main highlights of the...

1M ago

PHAT

Phathom Pharmaceuticals price target raised to $22 from $17 at Craig-Hallum

Craig-Hallum analyst Chase Knickerbocker raised the firm’s price target on Phathom Pharmaceuticals (PHAT) to $22 from $17 and...

1M ago

PHAT

Phathom Pharmaceuticals price target raised to $26 from $20 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Phathom Pharmaceuticals (PHAT) to $26 from $20 and keeps a...

1M ago

PHAT

Phathom Pharmaceuticals Reports Strong Q3 2025 Growth

Phathom Pharmaceuticals, Inc. ( ($PHAT) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

PHAT

Phathom Pharmaceuticals: Strong Q3 Performance and Promising Growth Drive Buy Rating

In a report released today, Joseph Stringer from Needham maintained a Buy rating on Phathom Pharmaceuticals, with a...

1M ago

PHAT

Phathom Pharmaceuticals reports Q3 adjusted EPS (15c), consensus (41c)

Reports Q3 revenue $49.5M, consensus $46.99M. “Our performance this quarter reinforces our belief in the strength of our...

1M ago

PHAT

Phathom Pharmaceuticals sees cash sufficient to fund operations in 2026

As of September 30, 2025, cash and cash equivalents were $135.2 million. Net cash usage was approximately $14...

1M ago

PHAT

Phathom Pharmaceuticals sees FY25 revenue $170M-$175M, consensus $170.4M

07:04 EDT Phathom Pharmaceuticals (PHAT) sees FY25 revenue $170M-$175M, consensus $170.4M Published first on TheFly – the ultimate...

1M ago

PHAT

Phathom Pharmaceuticals’ EoE Study: A Potential Game-Changer?

Phathom Pharmaceuticals, Inc. (($PHAT)) announced an update on their ongoing clinical study. Study Overview: Phathom Pharmaceuticals, Inc. is...

2M ago

PHAT

Phathom Pharmaceuticals’ Vonoprazan Pregnancy Study: A Market Game Changer?

Phathom Pharmaceuticals, Inc. (($PHAT)) announced an update on their ongoing clinical study. Phathom Pharmaceuticals, Inc. is conducting an...

2M ago

PHAT

PHAT FAQ

What was Phathom Pharmaceuticals’s price range in the past 12 months?

Phathom Pharmaceuticals lowest stock price was $2.21 and its highest was $16.45 in the past 12 months.

What is Phathom Pharmaceuticals’s market cap?

Phathom Pharmaceuticals’s market cap is $1.01B.

When is Phathom Pharmaceuticals’s upcoming earnings report date?

Phathom Pharmaceuticals’s upcoming earnings report date is Mar 03, 2026 which is in 80 days.

How were Phathom Pharmaceuticals’s earnings last quarter?

Phathom Pharmaceuticals released its earnings results on Oct 30, 2025. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.463 by $0.053.

Is Phathom Pharmaceuticals overvalued?

According to Wall Street analysts Phathom Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Phathom Pharmaceuticals pay dividends?

Phathom Pharmaceuticals does not currently pay dividends.

What is Phathom Pharmaceuticals’s EPS estimate?

Phathom Pharmaceuticals’s EPS estimate is -0.42.

How many shares outstanding does Phathom Pharmaceuticals have?

Phathom Pharmaceuticals has 71,138,440 shares outstanding.

What happened to Phathom Pharmaceuticals’s price movement after its last earnings report?

Phathom Pharmaceuticals reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.463. Following the earnings report the stock price went down -1.626%.

Which hedge fund is a major shareholder of Phathom Pharmaceuticals?

Currently, no hedge funds are holding shares in PHAT

Phathom Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-37.92%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Phathom Pharmaceuticals (PHAT) Earnings & Revenues

Historic Earnings Reports

PHAT Company Deck

PHAT Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Phathom Pharmaceuticals had a strong Q3 with significant revenue growth and a substantial reduction in operating expenses and cash usage. The company is effectively executing its gastroenterology-focused strategy. However, there are potential challenges such as the temporary impact of sales force realignment and ongoing uncertainty in TRIPLE PAK supply.View all PHAT earnings summaries

PHAT Stock 12 Month Forecast

Average Price Target

$25.40

▲(74.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","9":"$9","16":"$16","23":"$23","30":"$30"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9,16,23,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.94,16.021538461538462,17.103076923076923,18.184615384615384,19.266153846153845,20.347692307692306,21.42923076923077,22.51076923076923,23.592307692307692,24.673846153846153,25.755384615384614,26.836923076923078,27.918461538461536,{"y":29,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.94,15.744615384615384,16.549230769230768,17.353846153846153,18.158461538461538,18.963076923076922,19.767692307692307,20.57230769230769,21.376923076923077,22.18153846153846,22.986153846153847,23.79076923076923,24.595384615384614,{"y":25.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.94,15.02153846153846,15.103076923076923,15.184615384615384,15.266153846153847,15.347692307692308,15.429230769230768,15.510769230769231,15.592307692307692,15.673846153846153,15.755384615384616,15.836923076923076,15.918461538461539,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.71,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.99,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.12,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.36,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.64,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.29,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.94,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >